Search All News
Spotlighting new research from the Momen-Heravi lab on immunotherapy response in head and neck cancer and other solid tumor types.
New research by the labs of Nicholas Arpaia, PhD, (pictured) and Tal Danino, PhD, marks a major step forward in efforts to enlist non-pathogenic bacteria to combat cancer.
Results of a multi-center study, co-led by Dr. Richard Carvajal, demonstrates a promising new immunotherapy for patients with rare uveal melanoma.
Congratulations to Dr. Benjamin Izar, a recipient of the Schaefer Research Scholar award, supporting his work in drug resistance and novel immunotherapies.
- March 18, 2022
In a new content series, Notes from the Lab, we spotlight research by the Piero Dalerba lab that aims to predict resistance to immunotherapy in certain colon cancers.
- February 18, 2022
In a new study, researchers demonstrate that applying artificial intelligence to standard-of-care imaging can help predict how well immunotherapy will work for patients with melanoma.
- January 16, 2022
Two research teams led by experts in oncology and engineering have won pilot grants from the Herbert Irving Comprehensive Cancer Center and Columbia Engineering.
Source:CUIMC NewsroomMarch 5, 2021
Ben Izar, MD, and colleagues have created a new technique that can uncovertricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.
- February 19, 2021
Meet Dr. Robyn Gartrell, a physician-scientist focused on bringing cutting-edge cancer immunotherapies that have had success in treating adult cancers to childhood cancers.
- November 24, 2020
A physician-researcher in thoracic oncology, Dr. Catherine Shu has a focused interest in improving outcomes for lung cancer patients with resectable disease.
- October 5, 2020
Dr. Kathy Crew's work in breast cancer risk, prevention, and screening has been instrumental in the advancement of breast cancer research.
- July 19, 2020
The Human Immune Monitoring Core (HIMC) at CUIMC is a hub for comprehensive immune profiling and expert support for advanced immunological research studies.
- May 4, 2020
Dr. Matthew Dallos and colleagues have opened the first clinical trial testing an anti-IL-8 compound as a potential therapy against COVID-19.